The Lab of Adaptive Immunity and Homeostasis
@AndersenJT
Followers
2K
Following
5K
Media
346
Statuses
1K
Jan Terje Andersen, professor
Oslo, Norway
Joined January 2018
Happy to share a new story on a versatile technology allowing design of long-acting #antibodies with tailored target-dependent mode of actions. @NatureComms @UniOslo_MED @novonordiskfond @forskningsradet @CoE_PRIMA
nature.com
Nature Communications - Antibody based biologics are a rapidly growing class of therapeutics with interest to enhance their performance, distribution, longevity and effectivity. Here, authors...
0
4
18
New study out in @NatureComms! #FcRn biology-guided engineering of long-acting coagulation factor IX. @forskningsradet @Oslounivsykehus @UniOslo_MED
nature.com
Nature Communications - Coagulation factor IX (FIX) contributes to hemostasis through both plasma activity and binding to extravascular collagen IV. Here, the authors show that collagen binding of...
0
0
1
#Boston next week! Reach out to talk science and opportunities. #albumin #IgG #antibodies @AutheraAS @UniOslo @Oslounivsykehus @CoE_PRIMA
https://t.co/k1tDS5uzLF
0
0
1
Identification of a direct interaction between the Fab domains of IgG antibodies and human FcRn upon IgG-FcRn complex formation: Communications Biology, Published online: 12 June 2025; doi:10.1038/s42003-025-08252-zTwo orthogonal mass spectrometry… https://t.co/tHyjEq2WKV
0
3
5
The C-terminal end of #albumin can be cleaved, which reduces binding to #FcRn. As such, the plasma half-life drops from 3 weeks to about only 3-4 days in humans. This biology may have implications for design of the next generation of human albumin based therapeutics. @UniOslo_MED
1
1
3
In this review, we discuss the rise of #FcRn antagonists as a novel therapeutic class. @BioDrugsJournal
https://t.co/EMtU1qgQgK
@UniOslo_MED @Oslounivsykehus
0
0
0
FcRn protects IgG and albumin from catabolism, transports IgG across the placenta, and regulates IgG function. Blocking or augmenting FcRn can decrease autoimmune antibodies and enhance drug delivery. Learn more in the Review Article “Neonatal Fc Receptor — Biology and
1
33
100
New in JBC press: "Scientists' work describes an FcRn-driven mechanistic basis for induction of potent innate immune responses with a rHA-CpG conjugate design." Learn more: https://t.co/M0F0oGbwdi
0
2
2
Torleif Tollefsrud Gjølberg and colleagues describe FcRn biology, and give an overview of the current clinical pipeline of FcRn antagonists in autoimmune diseases. #neonatalFcReceptor #autoimmunedisease #OpenAccess
https://t.co/SvOaWbuBVs
link.springer.com
BioDrugs - Autoimmune diseases are highly prevalent and affect people at all ages, women more often than men. The most prominent immunological manifestation is the production of antibodies directed...
0
1
2
Talenter og reisen! Les om Simones vei fra Forskerlinja på Ullern vg skole til @unioslo@UniOslo_MED @Oslounivsykehus til CEO i @AutheraAS. @ShareLabOslo @OsloSciencePark @OsloScienceCity
skolesamarbeid.oslocancercluster.no
Simone Mester er administrerende direktør i bioteknologiselskapet Authera. I knivskarp internasjonal konkurranse med 800 andre kvinner fra hele EU, får hun som én av 40 kvinner, hele 75.000 euro i...
0
1
2
Listen to Careers in Discovery where @TorleifGj , CSO and co-founder of @AutheraAS takes us through the company's journey from its academic beginnings @UniOslo_MED @UiO_LifeSci and @Oslounivsykehus
0
0
0
We welcome Madicken Bildsten as a PhD student in our lab and @CoE_PRIMA🎈She will work on protein engineering strategies targeting cancer. Lab co-supervision by Nikoline Rasmussen and collaboration with the lab of @JOlweus 🔬@forskningsradet @UniOslo_MED @Oslounivsykehus
0
0
5
Thanks to Laura Tran from @TheScientistLLC for highlighting one of the recents scientific articles about #antibodies with pH-dependent antigen binding properties from @CAT4Science at @DTUtweet and @AndersenJT @UniOslo: https://t.co/OSmYQwScse Orig Article: https://t.co/r5flUJ1XQ7
3
13
54
A warm welcome to our new lab member Lilli Bay! 🎈As a postdoc she will explore protein engineering strategies in the context of two favorite immune receptors; #FcRn and #TRIM21. Funded by @forskningsradet. @CoE_PRIMA @UniOslo_MED @OsloSciencePark @Oslounivsykehus
0
0
15
Proud of @AutheraAS and @SimoneMester_ From master's degree to PhD to CEO in 2022. Simone is one of the winners of @womentecheurope! Thank you for the support. @forskningsradet @OsloSciencePark
medwatch.no
I hard konkurranse med 800 søkere fra hele Europa har fire ledere av norske biotekselskap fått WomenTechEUs stipend på 75.000 euro.
0
1
6
A seminar celebrating 🎈@DrRHatchett's honorary doctorate at @UniOslo_MED! @CEPIvaccines @CoE_PRIMA @Oslounivsykehus @Folkehelseinst @NFdep @Kunnskapsdep
0
0
1
Last week was fun 🎈 Mark Cragg in Oslo as Visiting Professor of @CoE_PRIMA. Engaging talks and discussions on immunotherapy and how to engineer #antibodies for agonism. @unisouthampton @UniOslo_MED @forskningsradet @NSImmun
0
1
4
On the cover of a magazine! 🎈Great collaboration with @AndreasLaustsen and the team🔬
Cool to see our article "Engineering of pH-dependent antigen binding properties for toxin-targeting IgG1 antibodies using light-chain shuffling" on the cover of @Structure_CP! https://t.co/pIjmN2jWlW Read paper here: https://t.co/r5flUJ2vFF
0
1
6
Cool to see our article "Engineering of pH-dependent antigen binding properties for toxin-targeting IgG1 antibodies using light-chain shuffling" on the cover of @Structure_CP! https://t.co/pIjmN2jWlW Read paper here: https://t.co/r5flUJ2vFF
1
7
14
Excited to share our new article “Engineering of #pH-dependent antigen binding properties for #toxin-targeting IgG1 #antibodies using light-chain shuffling”, which has just been published in 'Structure' by @CellCellPress: https://t.co/OIPpoc3ejm
1
12
48